Heather Turner predicts LB Pharma will be on the cusp of schizophrenia approval, have successful bipolar depression phase three data, and positive phase two adjunctive MDD data by 2029.
“The best case scenario in 2029 would be that we are, you know, on the cusp of approval in schizophrenia, that we are successful in bipolar, depression and moving to phase three and, you know, on the verge of reading out what hopefully will be positive data in in a phase two adjunctive MDD trial.”
→ Read the source episode
Our resolution criterion
disputableBy end of 2029, LB Pharma has submitted or is preparing to submit NDA for schizophrenia indication; has positive phase three bipolar depression data; has positive phase two adjunctive MDD data.
More from The Long Run with Luke Timmerman
Matai Mammen predicts Parabolas will eventually conduct a basket trial using a genetic signature to enroll multiple tumor types responsive to zolucatotide
Matai Mammen predicts Parabolas will initiate Phase 3 trials for zolucatotide in desmoid tumors in H1 2027
Maize Therapeutics will determine within the next year whether its APOL1 and SLC6A19 programs pass phase two clinical trial scrutiny.
Maize Therapeutics will have initiated a pivotal study on APOL1 and advanced other programs through mid-stage development by August 2027.
Avalon will initiate Phase 3 trials for APL1 and APO2 following Phase 2 data readouts in 2027
Heather Turner predicts LB102 will demonstrate efficacy across multiple serious neuropsychiatric indications beyond schizophrenia.
Summaries are ours; the quote is a verbatim transcript excerpt. Our resolution criteria are editorial and disputable. How this works.